Form 4: Catalyst Pharmaceuticals Director Charles B. O'Keeffe Acquires Shares and Options

Director Charles B. O'Keeffe of Catalyst Pharmaceuticals acquired stock options and restricted stock units on November 21, 2024, increasing his holdings in the company.

Summary

• Charles B. O'Keeffe, a director at Catalyst Pharmaceuticals, reported acquiring 23,248 stock options and 2,841 restricted stock units on November 21, 2024.
• The stock options have an exercise price of $21.12 and vest in three equal tranches on November 21, 2025, 2026, and 2027.
• The restricted stock units represent a contingent right to receive one share of common stock upon vesting.
• Following these transactions, O'Keeffe's direct holdings include 252,179 shares of common stock and 255,020 restricted stock units.

Sentiment

Score: 7

Explanation: The document reflects a positive sentiment as it shows a director increasing their stake in the company, which is generally seen as a good sign. However, it is a routine filing and not a major event.

Positives

• The acquisition of stock options and restricted stock units by a director signals confidence in the company's future performance.
• The vesting schedule of the options encourages long-term commitment from the director.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders make transactions in their company's stock. It provides transparency into the holdings of company directors.

Comparison to Industry Standards

• Form 4 filings are a standard practice for all publicly traded companies in the US, ensuring transparency of insider transactions.
• The vesting schedule of the options is typical for executive compensation packages, aligning the director's interests with the long-term performance of the company.
• The exercise price of $21.12 is a specific value related to the company's stock at the time of the grant.

Stakeholder Impact

• The increased holdings by a director may positively influence investor confidence.
• The vesting schedule of the options aligns the director's interests with the long-term performance of the company, which is beneficial for shareholders.

Key Dates

Keywords

Catalyst Pharmaceuticals, stock options, restricted stock units, insider trading, beneficial ownership, director, CPRX